Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repros completes patient dosing in Phase 2 Proellex trial
The Phase 2 ZP-204 study is a five arm dose escalation study in which up to 12 women with diagnosed endometriosis or uterine fibroids were randomized to 1,
The Phase 2 ZP-204 study is a five arm dose escalation study in which up to 12 women with diagnosed endometriosis or uterine fibroids were randomized to 1,
VelQuest is specialized in paperless lab execution systems supporting current Good Manufacturing Practices (cGMP) for FDA-regulated industries including pharmaceuticals and biotechnology organizations. Following the acquisition, Accelrys’ software portfolio
Quture’s new science and technology will introduce electronic performance measurement to empower hospitals and surgery centers to measure clinical performance on the InterSystems Corporation technology platform. Rural and
Tivozanib is a potent, selective and continuous inhibitor of all three vascular endothelial growth factor (VEGF) receptors that are designed to optimize VEGF blockade while minimizing off-target toxicities.
Lynovex is the company’s novel dual mucolytic-antibacterial drug for the treatment of cystic fibrosis (CF). According to the company, Lynovex (Cysteamine) is the first drug candidate with a
The GlobalMed i8500 Series Mobile Telemedicine Carts powered by HP combine the power of the HP Z210 SFF(Small Form Factor) Workstations with HP L2105 Widescreen LCD Touchscreen monitors
The FDA approved Onfi for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older. Onfi is an oral anti-epileptic drug (AED) of
APG101, a first-in-class, fully human protein is an inhibitor of the CD95 ligand (CD95L). The company will use the proceeds to develop APG101, and for the production of
The randomized double blind placebo controlled trial enrolled a total of 240 patients with low to moderate grade cervical intraepithelial neoplasia (CIN1-2) to evaluate the optimal dose of
According to Mozambique health minister Alexandre Manguele, the initial stocks of ARVs manufactured jointly with Brazil would be ready by July 2012 , telegraph.co.uk reported. The initiative makes